FIELD: medicine.
SUBSTANCE: present invention refers to medicine, particularly to pharmacology, and describes a method for correction of disturbed functional activity of platelets, consisting in using Melaxen as a corrector for the disaggregation and hyperaggregation state of the platelets to be orally administered into white non-linear mature rats in a dose of 1 mg/kg once a day within the 7-day therapeutic course.
EFFECT: invention aims at extending the range of preparations having an ability to control the aggregation properties of platelets depending on the nature of the haemostatic disorders.
4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTION OF CHRONIC TOXIC COAGULOPATHY IN EXPERIMENTAL ANIMALS | 2018 |
|
RU2683723C1 |
METHOD FOR PREVENTING CHRONIC LEAD COAGULOPATHY IN EXPERIMENTAL ANIMALS | 2019 |
|
RU2706386C1 |
METHOD FOR EVALUATING AGGREGATION PROPERTIES OF BLOOD PLATELETS | 2001 |
|
RU2213976C2 |
METHOD FOR PREVENTION OF THROMBOSIS IN INDIVIDUALS SUFFERING CARDIOVASCULAR DISEASES AND CHRONIC PAIN | 2013 |
|
RU2528904C1 |
METHOD FOR EVALUATION OF THROMBOCYTE AGGREGATION | 2009 |
|
RU2390027C1 |
METHOD FOR PREVENTING CHRONIC MOLYBDENUM COAGULOPATHY | 2020 |
|
RU2739690C1 |
AGENT POSSESSING ANTIAGGREGANT ACTIVITY | 2019 |
|
RU2696583C1 |
METHOD OF DETECTING DISTURBANCE OF THROMBOCYTE AGGREGATION | 2009 |
|
RU2393485C1 |
METHOD FOR PREVENTION OF TOXIC COAGULOPATHY IN RATS | 2022 |
|
RU2794030C1 |
COMBINED ANTIAGGREGANT AND ANTIOXIDANT | 2010 |
|
RU2430728C1 |
Authors
Dates
2013-11-10—Published
2012-07-17—Filed